Can Vraylar (cariprazine) be used during the first trimester of pregnancy?

Vraylar (Cariprazine) Should Be Avoided During the First Trimester of Pregnancy

Vraylar (cariprazine) is not recommended during the first trimester of pregnancy due to lack of human safety data and evidence of fetal harm in animal studies, including skeletal malformations and developmental toxicity at clinically relevant doses. 1

FDA Drug Label Evidence

The FDA label for Vraylar provides critical information about pregnancy risks:

• No human pregnancy data exists to inform drug-associated risks for birth defects or miscarriage 1
• Animal studies demonstrate fetal harm: In rats, cariprazine caused skeletal malformations (bent limb bones, scapula, humerus), reduced fetal body weight, and decreased male anogenital distance at doses 0.2 to 3.5 times the maximum recommended human dose (MRHD) of 6 mg/day 1
• Critical pharmacokinetic concern: The major active metabolite (DDCAR) has been detected in adult patients up to 12 weeks after discontinuation, meaning fetal exposure could continue long after stopping the medication 1

Third Trimester Risks

If exposure occurs later in pregnancy:

• Neonates are at risk for extrapyramidal and/or withdrawal symptoms including agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, and feeding disorders 1
• These symptoms vary in severity; some neonates recover within hours while others require prolonged hospitalization 1
• Monitor neonates closely for these symptoms and manage appropriately 1

Clinical Decision-Making Algorithm

If pregnancy is discovered while taking Vraylar:

1. Immediately consult with psychiatry and obstetrics to assess psychiatric stability and pregnancy timing
2. First trimester exposure: Strongly consider discontinuation given animal teratogenicity data and lack of human safety information
3. Consider the 12-week metabolite window: Even after stopping, active metabolites persist for up to 3 months
4. Weigh relapse risk: For severe psychiatric illness (schizophrenia, bipolar disorder), the risk-benefit calculation must account for maternal and fetal risks of untreated psychiatric disease
5. Alternative agents: Consider switching to antipsychotics with more established pregnancy safety profiles if continuation of antipsychotic treatment is necessary

Limited Real-World Experience

One case report describes successful cariprazine maintenance throughout pregnancy without adverse maternal or fetal outcomes 2. However, a single case report cannot establish safety, particularly given the strong animal data showing developmental toxicity.

Pregnancy Registry

The FDA label mandates informing patients about the National Pregnancy Registry for Atypical Antipsychotics (1-866-961-2388) to contribute to the limited knowledge base 1.

Common Pitfalls to Avoid

• Do not assume safety based on the single published case report 2 - this represents insufficient evidence against animal teratogenicity data
• Do not forget the prolonged metabolite half-life - stopping Vraylar in early pregnancy may not prevent first trimester exposure due to persistent active metabolites
• Do not delay the risk-benefit discussion - the decision to continue or discontinue requires immediate multidisciplinary consultation given the complexity of balancing psychiatric stability against fetal risk

The safest approach is to avoid Vraylar during the first trimester when organogenesis occurs and teratogenic risk is highest, consistent with general principles for managing psychiatric medications in pregnancy.